SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-192827
Filing Date
2023-07-25
Accepted
2023-07-25 08:47:00
Documents
12
Period of Report
2023-07-25
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K d540952d8k.htm   iXBRL 8-K 23488
  Complete submission text file 0001193125-23-192827.txt   148580

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tars-20230725.xsd EX-101.SCH 2841
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tars-20230725_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tars-20230725_pre.xml EX-101.PRE 11701
6 EXTRACTED XBRL INSTANCE DOCUMENT d540952d8k_htm.xml XML 3526
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39614 | Film No.: 231106651
SIC: 2836 Biological Products, (No Diagnostic Substances)